Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies
{{output}}
Microsatellite-stable (MSS) colorectal cancer (CRC), comprising 85% to 95% of all CRC cases, represents a significant therapeutic challenge in the era of cancer immunotherapy. Unlike microsatellite instability-high tumors that demonstrate remarkable responses ... ...
